Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Issue 7 (24th July 2019)

• Record Type: Journal Article
• Authors: Sabbagh, Sara; Pinal-Fernandez, Iago; Kishi, Takayuki; Targoff, Ira N; Miller, Frederick W; Rider, Lisa G; Mammen, Andrew Lee
• Is Part Of: Annals of the rheumatic diseases. Volume 78:Issue 7(2019)
• Page Start: 988
• Publication Date: 2019-07-24
• Subjects: myositis -- juvenile idiopathic inflammatory myopathies -- anti-ro52 autoantibodies -- myositis associated autoantibodies -- interstitial lung disease; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-215004
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objectives: Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis. Methods: We screened sera from 302 patients with juvenile dermatomyositis (JDM), 25 patients with juvenile polymyositis (JPM) and 44 patients with juvenile connective tissue disease–myositis overlap (JCTM) for anti-Ro52 autoantibodies by ELISA. Clinical characteristics were compared between myositis patients with and without anti-Ro52 autoantibodies. Results: Anti-Ro52 autoantibodies were found in 14% patients with JDM, 12% with JPM and 18% with JCTM. Anti-Ro52 autoantibodies were more frequent in patients with antiaminoacyl tRNA synthetase (64%, p<0.001) and anti-MDA5 (31%, p<0.05) autoantibodies. After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001). Disease course was more frequently chronic, remission was less common, and an increased number of medications was received in anti-Ro52 positive patients. Conclusions: Anti-Ro52 autoantibodies are present in 14% of patients with juvenile myositis and are strongly associated with anti-MDA5 and antiaminoacyl tRNA synthetase autoantibodies. In all patients with juvenile myositis, those with anti-Ro52 autoantibodies were more likely to have ILD. Furthermore, patients with anti-Ro52 autoantibodies have more severe disease and a poorer prognosis.